1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Starling Oncology director Brad Hively told the company on September 1, 2026 that he will not stand for re-election to the Board at the 2027 annual meeting. He remains a director until that meeting but immediately stepped down as Vice Chairman and from the Compliance Committee and other Board committees. The company says the decision did not stem from any disagreement over its operations, policies or practices.
Brad Hively will not stand for re-election to the Board at the 2027 annual meeting of stockholders.
Hively remains a director until the 2027 annual meeting, per the filing.
Effective immediately, Hively no longer serves as Vice Chairman or on the Compliance Committee or other Board committees.
The filing states the decision was not the result of any disagreement with the company.
Barfresh's chief financial officer, Lisa Roger, is retiring with a last day of September 1, 2026, and chief executive Riccardo Delle Coste will serve as interim CFO. The company also named Philip Meneses as Controller (principal accounting officer) effective August 28, 2026, and director Alexander H. Ware, who chaired the Audit Committee, will resign effective September 15, 2026.
CFO Lisa Roger's last day is September 1, 2026; CEO Riccardo Delle Coste will serve as interim CFO.
Philip Meneses appointed Controller effective August 28, 2026, with an annual base salary of $130,000, bonus eligibility of up to 15% of that amount, and 20,800 restricted stock units subject to vesting.
Director Alexander H. Ware gave notice on August 31, 2026 of his resignation effective September 15, 2026; he chaired the Audit Committee. The filing says the resignation was not due to a disagreement with the company.
Chan Heng Fai resigned as Chairman and Chief Executive Officer of HWH International Inc. effective September 1, 2026, and will remain a director. Liu Ming Hui becomes Chairman and Liu Ming Xing becomes CEO; both are brothers tied to majority stockholder Smart Dynamics Technology Limited, which bought shares and warrants from the company on August 10, 2026. The filing names HWH International Inc. (Nasdaq: HWH), not EnerSyn Global Inc., so the company identity in the request should be checked.
Chan Heng Fai, 81, resigned as Chairman and CEO on September 1, 2026, and continues as a board member.
Liu Ming Hui was appointed Chairman (press release says Executive Chairman); Liu Ming Xing was appointed CEO.
Liu Ming Hui and Liu Ming Xing are brothers; Liu Ming Hui owns Smart Dynamics, the majority stockholder.
On August 10, 2026, Smart Dynamics bought 20,000,000 common shares and warrants for up to 160,000,000 shares for $10,000,000 under a securities purchase agreement amended June 8, 2026.
Amrize Ltd's Board appointed Zane Nielsen as Chief Accounting Officer and Corporate Controller, effective September 1, 2026, replacing Richard Hoffman as principal accounting officer. Nielsen has been the company's Head of External Reporting since its June 2025 spin-off from Holcim Ltd. The change is administrative in nature and the filing discloses no financial results.
Zane Nielsen appointed Chief Accounting Officer and Corporate Controller, effective September 1, 2026
Nielsen replaces Richard Hoffman as principal accounting officer
Offer Letter sets a $350,000 base salary, 50% annual bonus target and 60% long-term incentive target beginning in 2027
Quantum Corporation named Hiral A. Patel as Chief Accounting Officer and Principal Accounting Officer, effective September 1, 2026, replacing no predecessor named in the filing. The filing sets her base salary at $335,000, a target bonus of 50% of salary, and a grant of 50,000 restricted stock units, along with change of control and standard severance terms. The appointment is a routine finance leadership change with no reported financial results.
Hiral A. Patel appointed Chief Accounting Officer and Principal Accounting Officer, effective September 1, 2026
Offer letter: base salary of $335,000 and target bonus of 50% of base salary
Inducement grant of 50,000 RSUs vesting in three equal annual installments, expected effective on or around October 1, 2026
Change of control agreement provides 12 months of base salary plus 100% of target bonus if terminated within 3 months before to 12 months after a change of control
Intellinetics CEO Matthew Chretien notified the company on August 26, 2026, that he will retire and resign as Secretary and Chief Strategy Officer, effective September 1, 2026. The company expects to enter a separation agreement with him, but the material terms have not been determined and will be disclosed later if required.
Matthew Chretien notified the company on August 26, 2026, of his retirement.
His resignations as Secretary and Chief Strategy Officer take effect September 1, 2026.
A separation agreement is expected, but its material terms have not been determined.
The 8-K is signed by Alison Forsythe, President and Chief Executive Officer, and dated September 1, 2026.
Polaryx Therapeutics appointed Will Charlton, M.D., M.A.S., as its Chief Medical Officer, effective September 1, 2026, ahead of the planned SOTERIA Phase 2 trial start in the fourth quarter of 2026. The filing describes his prior roles as Chief Medical Officer at Spruce Biosciences and senior clinical development executive at Tyra Biosciences, and the company says his experience supports its clinical leadership. The filing contains no financial results or guidance, so the appointment is a leadership change rather than a change in reported performance.
Will Charlton, M.D., M.A.S., appointed Chief Medical Officer effective September 1, 2026; appointment announced August 27, 2026 and disclosed in a press release dated September 1, 2026
Previously Senior Vice President, Clinical Development, Skeletal Dysplasia at Tyra Biosciences (March 2025 to June 2026) and Chief Medical Officer at Spruce Biosciences (March 2022 to January 2025)
Company plans to initiate the SOTERIA Phase 2 trial of lead candidate PLX-200 in the fourth quarter of 2026; the company received an FDA safe to proceed letter in October 2025
Vertex Pharmaceuticals appointed Jonathan Poole as Executive Vice President and Chief Financial Officer on August 27, 2026, effective January 1, 2027. Charles F. Wagner, Jr. will stop serving as CFO on that date but will remain Executive Vice President and Chief Operating Officer. The filing discloses Mr. Poole's salary, bonus target and severance terms, which shareholders may review in the 10-Q exhibits later.
Jonathan Poole, 51, becomes EVP and CFO effective January 1, 2027, having been Senior Vice President, Finance at Vertex since March 2020
Charles F. Wagner, Jr. ceases to be CFO on the effective date and remains EVP and Chief Operating Officer
Poole's base salary is $750,000, with a target annual bonus of 90% of base salary
Severance on termination without cause or for good reason is 100% of base salary and target bonus; the change of control agreement covers the period from 90 days before to 12 months after a change of control
Raymond James Financial appointed William Weatherford, managing partner of Weatherford Capital, as a director, effective December 15, 2026, and increased the board from 12 to 13 seats. The company also declared a $0.54 per share quarterly dividend, payable October 15, 2026, and the filing reports no change to financial results or guidance.
Weatherford joins the Audit Committee and Risk Committee and is determined by the board to be independent; his appointment takes effect December 15, 2026.
The board size increased from twelve to thirteen directors.
Quarterly dividend of $0.54 per share, payable October 15, 2026 to shareholders of record on October 1, 2026.
FranklinCovey announced several executive leadership changes effective September 1, 2026, including M. Sean Covey moving from President, Education Division to Chief Product Officer and John Buchanan joining as Executive Vice President, Education. Operations chief Colleen Dom will retire effective June 1, 2027, with Adam Sherman set to succeed her. The changes concern senior management roles and do not include any reported financial results.
M. Sean Covey becomes Chief Product Officer effective September 1, 2026; his compensation will not change
John Buchanan joins as Executive Vice President, Education effective September 1, 2026, most recently Chief Growth Officer at GoGuardian
Colleen Dom retires as Executive Vice President, Operations effective June 1, 2027, with transition compensation totaling $98,000 plus an incremental short-term incentive award
Adam Sherman, Senior Vice President, Revenue and Customer Operations, will succeed Dom effective June 1, 2027
Avis Budget Group announced that Ravi Simhambhatla, Executive Vice President and Chief Digital & Innovation Officer, will leave the company. He will stay in his current role until September 30, 2026 to ensure a smooth transition. The filing contains no financial results or replacement details.
Ravi Simhambhatla, Executive Vice President and Chief Digital & Innovation Officer, is leaving the company
He remains in his current position until September 30, 2026
Callan JMB director Mark Meller resigned effective immediately on August 26, 2026, from the board and his roles as audit committee chair and governance and compensation committee member. The filing says the resignation was not due to any disagreement with the company on operations, policies or practices, and it ties the board change to an August 19, 2026 asset purchase agreement with Reger Oil, Inc. for oil and gas assets.
Mark Meller resigned from the board and as audit committee chair effective immediately on August 26, 2026.
If the Reger Oil asset purchase closes, holders of a majority of the stated value of Series A perpetual convertible preferred stock issued to the seller will nominate and elect a replacement director.
If the transaction does not close, remaining directors will fill the vacancy under the company's bylaws.
The filing states the resignation was not the result of any disagreement with the company.
Exodus Movement, Inc. disclosed that two of its officers, Jon Paul Richardson and Daniel Castagnoli, voluntarily cancelled all of their outstanding restricted stock units on August 31, 2026. The company says the cancellation adds share capacity under its 2026 Stock Incentive Plan to compensate employees and service providers tied to its long-term strategy and the integration of Monavate and Baanx.
Richardson cancelled 273,278 restricted stock units and Castagnoli cancelled 233,218 on August 31, 2026.
The cancelled units represented all of each officer's outstanding restricted stock units.
The freed share capacity is available under the 2026 Stock Incentive Plan for employee and service provider compensation.
The filing was signed September 1, 2026 by CFO James Gernetzke.
Greenlight Capital Re appointed John Welch as an independent director of the company and of Greenlight Reinsurance, effective September 1, 2026, and added him to the Audit, Compensation and Underwriting committees. The company also announced that Ariel Warszawski, elected by shareholders at its July 28, 2026 annual meeting, has joined the board. The filing describes board additions but gives no financial results, and the Greenlight Re appointment is subject to Cayman Islands Monetary Authority approval.
John Welch, age 61, appointed independent director effective September 1, 2026, and named to the Audit, Compensation and Underwriting committees
Welch's appointment to Greenlight Reinsurance, Ltd. board requires approval from the Cayman Islands Monetary Authority
Welch was Group Chief Underwriting Officer of Aspen Insurance Holdings from July 2025 to February 2026
Ariel Warszawski was elected to the board by shareholders at the July 28, 2026 Annual General Meeting
Mohawk Industries said on September 1, 2026 that An Nuyttens, a former Solvay executive, will become president of its Flooring Rest of the World segment effective mid-October, succeeding Paul De Cock, who has led the segment on an interim basis. The filing also says De Cock becomes chief executive officer effective September 30, 2026. The filing contains no financial results or guidance.
Nuyttens has more than 30 years of international leadership experience at Solvay, including senior executive roles in Europe and the United States.
Nuyttens takes over the segment effective mid-October 2026, replacing De Cock as interim leader.
Paul De Cock, Chief Operating Officer, becomes Chief Executive Officer effective September 30, 2026.
The segment serves customers in Europe, Asia-Pacific, Latin America and other international markets, including the Unilin business.
On August 28, 2026, Peoples Financial Services Corp. and its bank subsidiary amended the Supplemental Executive Retirement Plan agreement with former President Thomas P. Tulaney. The change adds a lifetime monthly payment after a twenty-year normal retirement benefit period, funded by an annuity contract the bank purchased.
Amendment approved August 28, 2026, with former President Thomas P. Tulaney
Bank bought an annuity contract to fund his normal retirement benefit under the SERP
If he survives the twenty-year benefit period, monthly payments continue for the rest of his life
Mannatech said J. Stanley Fredrick will retire from its Board and as Chairman effective September 1, 2026, citing personal reasons and no disagreement with the company. Robert Toth, the Board's Vice Chairman and a Class III director, was appointed Chairman effective the same date. The filing also sets out Toth's chairman pay and continues Fredrick's director retainer through December 31, 2026 to support the transition.
Fredrick notified the Board on August 26, 2026; his retirement takes effect September 1, 2026.
Toth joined the Board as Vice Chairman on December 1, 2024, and previously served on the Board from March 2008 through May 31, 2023.
Toth's first-year chairman pay includes $50,000 in additional annual compensation and an equity award valued at $50,000, with the grant deferred until shareholder approval allows enough shares.
From his second year, Toth receives an additional $100,000 chairman fee on top of standard director compensation.
Sprouts Farmers Market said its board appointed President and Chief Operating Officer Nick Konat as chief executive and a director, effective January 4, 2027, the first day of its 2027 fiscal year. Jack Sinclair, CEO since June 2019, will become executive chairman at that time. The filing does not include financial results or guidance tied to the change.
Nick Konat, age 49, has been president and chief operating officer since March 2022 and previously held roles at Petco and Target.
Konat's annual base salary will rise to $1,000,000 on January 4, 2027, with a target bonus of 125% of salary and long-term equity incentive opportunity of 600% of salary.
Jack Sinclair becomes executive chairman with a $900,000 base salary, a 100% target bonus and a 333% long-term equity incentive opportunity.
The board will expand to nine members, and Chairman Joseph Fortunato will serve as lead independent director from the same date.
Alamar Biosciences appointed Robert Ragusa to its board of directors, effective September 1, 2026, as a Class I director with a term expiring at the 2027 annual meeting. He also joined the audit, compensation, and nominating and corporate governance committees. The filing describes this as a routine board addition with no related person transactions disclosed.
Robert Ragusa appointed to the Board by action on August 28, 2026, effective September 1, 2026
Class I director; initial term expires at the 2027 Annual Meeting of Stockholders
Also named to Audit, Compensation, and Nominating and Corporate Governance Committees
Compensated under the Non-Employee Director Compensation Policy described in the April 17, 2026 final prospectus
On August 31, 2026, Flexible Solutions International announced that director and audit committee chair John Bientjes resigned, with the company saying the resignation was not due to any disagreement on operations, policies, or practices. Dr. Kim Reid was appointed as a director and audit committee member, and David Fynn was named audit committee chair. The changes are board and committee personnel moves, and the filing reports no financial figures.
John Bientjes resigned as a director and as audit committee chairman, after nearly thirty years of service, per the August 31, 2026 press release.
Dr. Kim Reid was appointed a director and audit committee member, to serve until the next Annual Meeting.
David Fynn was appointed audit committee chairman.
Otter Tail Corporation disclosed that directors Thomas J. Webb and Dr. Kathryn O. Johnson will retire from its Board of Directors when their current terms end at the 2027 Annual Meeting of Shareholders. Both moves follow the company's director retirement policy, and the company said neither reflects a disagreement with its operations, policies or procedures. The filing does not name replacements or address board size, so shareholders should watch for future board nominations.
Thomas J. Webb notified the company on August 28, 2026 that he will retire from the board at the end of his current term.
Kathryn O. Johnson notified the company on August 31, 2026 that she will retire, citing retirement age under the director retirement policy.
Both directors' terms expire at the 2027 Annual Meeting of Shareholders.
The company said neither departure results from a disagreement with its operations, policies or procedures.
Invivyd, Inc. appointed Chairman Marc Elia as Chief Executive Officer effective August 30, 2026, taking over as principal executive officer from William Duke, Jr., who remains Chief Financial Officer. The company also added Ian Sheffield to its board and named Ajay Royan Lead Independent Director, and the company said VYD2311 top-line data is still expected around the end of Q3 2026.
Marc Elia, Chairman since July 2022, became CEO effective August 30, 2026, and will also remain Chairman.
Elia's employment agreement provides a $750,000 base salary, a 70% target bonus, a $500,000 sign-on bonus, and an option to buy 10,700,000 shares.
Ian Sheffield was appointed a director on August 30, 2026, and Ajay Royan was named Lead Independent Director.
Invivyd expects top-line data from the VYD2311 program around the end of Q3 2026.
AptarGroup expanded its board from ten to eleven directors and appointed Gael Touya as a director effective September 1, 2026. Touya also became President and Chief Executive Officer that day, succeeding Stephan B. Tanda, who retired; the CEO change was previously disclosed in a March 17, 2026 filing. For shareholders, this filing confirms the leadership transition and board addition, with no financial results or guidance included.
Gael Touya appointed director effective September 1, 2026, with term expiring at the 2028 annual meeting.
Board size increased from ten to eleven directors on August 29, 2026.
Touya, formerly President of the Aptar Pharma segment, became CEO on September 1, 2026, succeeding Stephan B. Tanda.
Touya will not receive additional pay for board service; CEO compensation was disclosed in the March 17, 2026 8-K.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.